Although oral glucocorticoids are the treatment of choice for moderate to severe ulcerative pancolitis, their systemic side effects and adrenal suppression account for considerable morbidity. An oral glucocorticoid-conjugate (prodrug), budesonide-p-D-glucuronide, which is not absorbed in the small intestine but is hydrolysed by colonic bacterial and mucosal ,B-glucuronidase to release free budesonide into the colon was synthesised. The objective of this study was to compare treatment with budesonide-P-D-glucuronide with treatment with free budesonide by examining: (1) the healing of experimental colitis and (2) A new group of corticosteroids has recently been developed. In comparison with conventional corticosteroids, these drugs display a high degree of topical anti-inflammatory activity but do not show appreciable systemic activity. This unique activity ratio is achieved because a very high potency is coupled with rapid metabolism of the drug to products that have minimal or no biological activity. This rapid metabolism, also referred to as high first-pass liver metabolism, allows for a high therapeutic efficacy and high systemic tolerability.
P-D-glucuronide with treatment with free budesonide by examining: (1) the healing of experimental colitis and (2) the extent of adrenal suppression. Pancolitis was induced with 40/o acetic acid. Animals were then randomised to receive oral therapy for 72 hours with (1) budesonide-3-D-glucuronide, (2) free budesonide, or (3) vehicle. Drug efficacy and colitic healing was determined by measuring gross colonic ulceration, myeloperoxidase activity, and in vivo colonic fluid absorption. Adrenal suppression was determined by measuring plasma adrenocorticotrophic hormone and serum corticosterone. Vehicle-treated colitis animals had gross ulceration, increased myeloperoxidase activity, and net colonic fluid secretion. Treatment A new group of corticosteroids has recently been developed. In comparison with conventional corticosteroids, these drugs display a high degree of topical anti-inflammatory activity but do not show appreciable systemic activity. This unique activity ratio is achieved because a very high potency is coupled with rapid metabolism of the drug to products that have minimal or no biological activity. This rapid metabolism, also referred to as high first-pass liver metabolism, allows for a high therapeutic efficacy and high systemic tolerability.
Budesonide is a member of this group of steroids which display high first-pass liver metabolism. Budesonide is a non-halogenated glucocorticoid structurally related to 16- alpha-hydroxyprednisolone.4 Administration of this drug via inhalation has proved effective in the treatment of asthma and rhinitis. It also presented a low adverse drug event profile.4
Budesonide, given as an enema, has also proved superior to other glucocorticoids in the treatment of distal ulcerative colitis.5
Budesonide has now been formulated into an enterocapsule preparation which allows the drug to bypass the upper gastrointestinal tract, thus facilitating delivery of the active compound to the terminal ileum.6 Unfortunately, it was found that less than 5%/o of the compound was available beyond the ileum and caecum.6 Therefore, while this compound would be useful for the treatment of small intestinal Crohn's disease,7 it is not likely to have an appreciable effect on colonic inflammatory bowel disease. In addition, a recent dose ranging study showed that effective doses of budesonide (9 mg/d) cause significant adrenal suppression.8
Because of these problems, we designed and synthesised an orally administered, colonspecific budesonide prodrug (budesonide-,-D-glucuronide) with a delivery mechanism that would increase budesonide concentrations along the colon relative to systemic drug concentrations, thereby increasing colonic drug efficacy and decreasing systemic side effects.9 The advantage of colon-specific delivery has been already documented in the case of the non-steroidal anti-inflammatory agent 5-aminosalicylic acid. In that instance, the prodrugs sulphasalazine and olsalazine, from which the active drug is released in the colon by the action of microbial azoreductases, were used.10-'2 were: (1) to test the efficacy of budesonide prodrugs in treating experimentally induced colitis in rats and (2) to determine whether adrenocortical axis suppression occurred with administration of the budesonide prodrug. compromising neural or vascular integrity. The colon was cleansed of its luminal contents with 154 mM sodium chloride solution at 37°C, and the residual fluid was expressed manually through the rectum. Acetic acid (4%, 2 ml) was injected into the lumen of the colon through a 26 gauge needle passed obliquely through the colonic wall just distal to the occluding ligature. After 20 seconds 10 ml of air were injected to clear the acetic acid from the colon. The occluding ligature was removed and the midline incision closed. The animals were allowed to recover from the anaesthesia in a light-cycled room that provided free access to standard rat chow pellets (5001, Purina Mills Inc, St Louis, MO, USA) and water. All in vivo studies outlined below were carried out 72 hours after induction of colitis.
Methods

ADMINISTRATION OF BUDESONIDE PRODRUG
Budesonide-3-D-glucuronide was administered by oral gavage 24 and 48 hours after the induction of colitis. The budesonide conjugate solutions were prepared immediately before their oral administration; the appropriate volume of stock solution was mixed with 154 mM sodium chloride to a total volume of 1 ml (pH 7 4). Rats were administered doses of free budesonide and equivalent doses of the respective conjugate ranging from 0-0137 to 0 44 ,molIkg/d.
IN VIVO INTESTINAL FLUID ABSORPTION
Intestinal absorption of fluid was assessed as described previously. 15 Seventy two hours after the induction of colitis, rats were anaesthetised with pentobarbital (55 mg/kg) and atropine (0 5 mg/kg) and maintained at 37°C using a thermostatic heat lamp. The intestinal tract was exposed through a midline abdominal incision. An occluding ligature was placed at the caecal-ascending colon junction. Sodium chloride solution (1 54 mM, 37°C) was instilled into the proximal colon via a cannula inserted through an incision just distal to the proximal occluding ligature in order to flush out the luminal contents of the colon. Residual saline was emptied by gentle manual expression. A 12 cm long intestinal loop, beginning 2 cm below the caecal-colonic junction and extending distally to the peritoneal reflection, was created with ligatures. In isolating the loop, care was taken not to compromise mesenteric, vascular, or neural integrity. A 26 gauge needle was inserted obliquely through the outer muscle layer along the antimesenteric border, and 2 ml of sodium chloride solution (370C, 154 mM) were instilled into the empty loop. In no case was fluid leakage detected, and the loop was only mildly distended. Similar loops were formed in the jejunum, beginning 2 cm distal to the ligament of Trietz, and in the ileum, beginning 2 cm proximal to the ileocecal valve. The viscera were returned to the abdominal cavity, and the incision was closed. Sixty minutes after abdominal closure, the animals were given a pentobarbital overdose (240 mg/kg), and the intestinal loops were removed. The length of each loop was recorded. The intestinal loops were weighed, both full and empty, to determine residual intraluminal volume. Results were expressed as the difference between initial and residual loop volumes over the hour per centimetre of intestine.
MACROSCOPIC ULCERATION
The colon was rapidly excised, opened along its mesenteric border, and gently rinsed of its luminal contents with an iced 154 mM solution of sodium chloride. The colon was then placed flat, mucosal surface upwards, on a glass plate chilled to 4°C. A transparent acetate was placed 5 mm above the mucosal surface, and the area of ulceration and total surface area were traced by a single observer (NC). Areas in square centimetres were then calculated using a Zeiss computerised videoscope (Videoplan, Carl Zeiss Co, Toronto, ON, Canada). These data were also transformed into percentage-based terms expressing improvement in macroscopic ulceration; control animals scored 0%.
MYELOPEROXIDASE ACTIVITY
An assay of colonic myeloperoxidase activity was used to quantify neutrophil infiltration. The entire length of colon from the ascendingcaecal junction to the rectum was homogenised in 5 ml of 0/5% hexadecyltrimethylammonium bromide in 50 mM phosphate buffer (pH 6) using a polytron homogenizer (Brinkman Instruments, Rexdale, ON, Canada) three times for 30 seconds each at 4°C. The homogenate was then sonicated for 10 seconds and centrifuged. The supemate (0x 1 ml) was combined with 2 Blood (2 ml) was collected into evacuated blood collection tubes (Becton Dickinson Vacutainer Systems, Rutherford, NJ, USA) between the hours of 0800 and 1000 by intracardiac puncture. It was then centrifuged at 40C for 10 minutes at 4000 rpm (Centra-7, International Equipment Co, Needham Heights, MA, USA). The serum was removed and stored at -70'C before analysis. Stock anti-corticosterone antiserum (B3-163) was obtained from Endocrine Sciences RIA Reagents (Tarzana, CA, USA). Diluted antiserum was prepared by adding together 10 ml borate buffer (0 05 M, pH 8), 400 000 dpm of 1,2-3H-corticosterone, 0-2 ml of 10% bovine serum albumin in a borate buffer, 0-2 ml of 0-25% bovine gamma globulin in a borate buffer, and 100 RI of stock antiserum. The serum sample for analysis was thawed and placed in 12X75 mm test tube; it was then diluted with a borate buffer and incubated at 60°C for 30 minutes. The solution was transferred to a 2 ml conical tube (Kimax #45150, Fisher Scientific, Nepean, ON, Canada) and incubated with diluted antiserum at 370C for 45 minutes and then at room temperature for two hours. Saturated ammonium sulphate solution (0.25 ml) was added to the tube, and the mixture was centrifuged at 3000 rpm for 10 minutes to separate free and bound steroids. The supernate was decanted into a microvial (Simport Ltd, Quebec City, QB, Canada), 4 ml of a scintillation cocktail was added (Scintiverse, bio-HP, Fisher Scientific, Nepean, ON, Canada), and radioactivity was counted using a liquid scintillation counter (LKB Wallace, 1219 Rack Beta, Turka, Finland). 
PLASMA ADRENOCORTICOTROPIC HORMONE
Adrenocorticotropic hormone (ACTH) concentrations were determined using blood (3 ml) collected by intracardiac puncture between 0800 and 1000 hours after pentobarbital overdose of the animal. Blood was drawn into a chilled siliconised tube. The blood was then centrifuged at 40C for 10 solid phase products were measured in a gamma counter (Packard, Fisher Scientific, Nepean, ON, Canada). Since the complex occurs only in the presence of an intact ACTH molecule containing both N-terminal and C-terminal regions, the radioactivity of the bead bound complex is directly proportional to the amount of intact ACTH in the sample.
STATISTICS
Statistical analysis of the data was performed using repeated measure analysis of variance. When the overall analysis showed significance, the Student's t test was used to examine the location and significance of differences.
Results
IN VIVO COLONIC FLUID ABSORPTION
In vivo net colonic fluid absorption was used as one measure of the rate of repair of mucosal integrity taking place. Net colonic fluid absorption in sham operated controls (102-5 ( 9 9) pV/cm/h) was unaffected (113-0 (11.2)
,u/cm/h) by the highest dose of budesonide studied (0-44 pLmolkg/d). This result suggests that the budesonide we tested did not merely enhance existing intestinal fluid and electrolyte transport; changes in colonic fluid absorption were therefore a measure of injury and/or repair. nal Jejunal fluid absorption (149-6 (9-7) p1/cm/h) a was unaffected by either the induction of colitis nd or treatment with budesonide or its conjugate ,tic (Fig 2(A) ). In contrast, Figure 2 (B) shows that a 4% acetic acid colitis caused a significant the decrease in ileal in vivo fluid absorption. Both ss, budesonide and budesonide-p-D-glucuronide :u-improved ileal fluid absorption equally la- (Fig 2(B) ). Basal fluid absorption in the small dy, intestine was not stimulated in control animals rnd given even the highest dose of budesonide vas tested (0-44 ,umol/kg/d), indicating that fluid rnd absorption was a sensitive measure of funcrnd tional mucosal injury for the entire intestine. The data shown in Figure 6 show the effect of budesonide on plasma ACTH concentrations. becomes available systemically and, when administered with food, only 4% of the drug reaches beyond the caecum and into the colon.6 It is therefore unlikely that the present formulation of budesonide, orally administered controlled ileal release capsule, will be delivered to the colonic lumen in sufficient concentrations to be effective in treating colonic inflammatory bowel disease. In animal studies, budesonide administered by subcutaneous injection healed experimentally induced colitis.18 Furthermore, administration of budesonide directly to colonic mucosa in the form of an enema has been shown to promote the healing of experimentally induced rat colitis18-20 and human pouchitis.21 These results suggest that budesonide, if dispensed through the appropriate drug delivery system to achieve adequate colonic concentrations, may be effective in healing colitis. zd
We therefore synthesised a prodrug conjugate of budesonide, budesonide-p-Dglucuronide, which would readily deliver free active budesonide to the colonic lumen with minimal absorption of budesonide in the stomach and small intestine. The prodrug conjugate is increased size and is extremely ni-hydrophobic relative to free budesonide. are Because these properties render it poorly ree absorbed in the proximal intestine, the con-)% jugate reaches the large intestine where it is be hydrolysed to free budesonide and sodium he glucuronate. This delivery of high local eal concentrations of free budesonide to the ied colonic lumen causes raised mucosal concento trations of budesonide: lower effective oral ing doses of the prodrug conjugate can therefore he be used to reach these therapeutic levels in nal the colon and achieve colitis healing through de-the local effects of budesonide. As a result of ate the lower oral dose required for therapeutic Dse effect, and the limited small intestinal absorption of the conjugate, a reduction in systemic corticosteroid side effects should be observed. A further reduction in systemic exposure should result from hepatic metabolism of any free budesonide once it has been delivered to the colon and absorbed into the portal venous system. Assuming a bioavailability of 01, a large selective advantage should be noted when colonic delivery is evaluated using a kinetic model.9 This very effective colonic prodrug delivery system of budesonide will allow its use in the treatment of colitis, but by the nature of its design will not allow it to be used for small intestinal disease therapy. In vivo, colonic fluid absorption is a sensitive measure of mucosal functional absorptive injury.15 As shown in Figure 1 Neither free budesonide nor its conjugate had any effect on fluid absorption in the jejunum of rats with colitis. Furthermore, neither drug had any effect on fluid absorption in the jejunum, ileum, or colon of sham operated control rats. These results suggest that free budesonide and its conjugate do not simply stimulate intestinal fluid transport, but instead improved absorption in the ileum and colon by facilitating the repair of the mucosal injury.
The healing of the fluid absorptive injury observed in the ileum of colitic animals (Fig 2(B) (Fig 4) .
It is therefore unlikely that budesonide-s-Dglucuronide's beneficial effects occur as a consequence of neutrophil migration inhibition: these are more probably the result of actions exerted at another step in the inflammatory process. Indeed, Jacobson et al have recently shown that in the trinitrobenzene sulphonic acid model of colitis, administration of budesonide prevents intestinal injury but does not alter myeloperoxidase activity. 20 Since adrenosuppression is directly related to the levels of exogenous free glucocorticoid circulating in the blood stream, we hypothesised that budesonide-p-D-glucuronide treatment should cause less adrenosuppression than same dose treatment with free budesonide. In humans, ACTH directly regulates the production of cortisone, while in the rat it regulates the production of corticosterone. Measurement of ACTH and corticosterone values is a sensitive means of determining the degree of adrenosuppression in rats. Figures 5  and 6 show that at every dose tested budesonide-3-D-glucuronide had a limited effect on ACTH and corticosterone values. This is in contrast to free budesonide administration, which caused a statistically significant adrenosuppression.
The orally administered, colon specific, budesonide prodrug conjugate, budesonide-P-D-glucuronide, improves the healing of experimentally induced colitis with less adrenosuppression than free budesonide. The development of colon specific glucocorticoid prodrugs may thus prove effective as novel therapy in treating human colonic inflammatory bowel disease without causing systemic side effects.
